

33944

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/937991

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**


INTERNATIONAL APPLICATION NO. PCT/JP00/02012	INTERNATIONAL FILING DATE 30 March 2000 (30.03.00)	PRIORITY DATE CLAIMED 02 April 1999 (02.04.99)
TITLE OF INVENTION FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL INSTRUMENTS AND DRUGS BY USING THE SAME		
APPLICANT(S) FOR DO/EO/US YURA, Hirofumi; SAITO, Yoshio; ISHIHARA, Masayuki; ONO, Katsuaki; ISHIKAWA, Keiichi		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information:
 - English translation of Amendments Under Article 34 of PCT filed on October 27, 2000
 - English translation of Amendments Under Article 34 of PCT filed on March 30, 2001

U.S. APPLICATION NO. 09/937991	INTERNATIONAL APPLICATION NO. PCT/JP00/02012	ATTORNEY'S DOCKET NUMBER 33944		
21. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):				
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....		\$1000.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO		\$860.00		
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO		\$710.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)		\$690.00		
International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4).....		\$100.00		
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 860.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 130.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	6 - 20 =	0	x \$18.00	\$ -----
Independent claims	1 - 3 =	0	x \$80.00	\$ -----
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 270.00
TOTAL OF ABOVE CALCULATIONS =				\$ 1,260.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			+ \$ 630.00	
SUBTOTAL =				\$ 630.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ -----
TOTAL NATIONAL FEE =				\$ 630.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$ -----
TOTAL FEES ENCLOSED =				\$ 630.00
			Amount to be refunded:	\$
			charged:	\$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$ 630.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>16-0820</u>. A duplicate copy of this sheet is enclosed. Order no. 33944</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO:</p> <p> 00116 PATENT & TRADEMARK OFFICE</p> <p> SIGNATURE Jeffrey J. Sopko</p> <p>NAME 27676</p> <p>REGISTRATION NUMBER</p>				

09/937991

"EXPRESS MAIL" MAILING LABEL CERTIFICATE

Re: U.S. PCT-based Patent Application for
"FUNCTIONALIZED GLYCOSAMINOGLYCAN POLYMER AND MEDICAL
INSTRUMENTS AND DRUGS BY USING THE SAME"
International Application No.: PCT/JP00/02012
International Filing Date: March 30, 2000
Attorney's Docket No.: 33944

"Express Mail" mailing label number EL609748154US

Date of Deposit September 28, 2001

I hereby certify that this paper or fee is being deposited with the
United States Postal Service "Express Mail Post Office to
Addressee" service under 37 C.F.R. § 1.10 on the date indicated
above and is addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231

Janet Morrison

Printed Name of Person Mailing Paper or Fee

Janet Morrison

Signature of Person Mailing Paper or Fee